Compare Nu Holdings Ltd (NU) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Revvity Inc — how do they compare? Nu Holdings Ltd trades at $13.72 (market cap $65.94B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Nu Holdings Ltd is far larger — about 5.1× Revvity Inc's market cap, and Revvity Inc pays a 0.24% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals.
| NU | RVTY | |
|---|---|---|
Market Cap | $65.94B | $12.91B |
Sector | Financials | Technology |
52-Week High | $18.76 | $117.75 |
52-Week Low | $11.60 | $82.26 |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU stock trades at $13.615, down 1.77% on the day, amid bearish technical signals but strong fundamentals. Revenue grew from $3.0B in 2022 to $10.63B in 2025, with net income turning positive to $2.87B. The company recently announced a Brazilian banking license acquisition (PYMNTS, 2026-07-22), supporting expansion. Analysts maintain a buy consensus with a $14.98 target, though recent earnings misses and competitive pressures pose headwinds.
Outlook: NU's robust growth trajectory and high ROE (30.04% as of 2025) offer upside, but technical weakness and Latin American market risks require caution. The Q2 2026 earnings report on August 13 (Defense World, 2026-08-12) is a key catalyst, with expectations of $0.1984 EPS. Investors should weigh strong profitability against bearish momentum and rising competition.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
